WE CLAIM:

1. An amorphous form of moxifloxacin hydrochloride.

2. The amorphous form of moxifloxacin hydrochloride of claim 1, wherein the moxifloxacin hydrochloride has the infrared spectrum of Figure 1.

3. The amorphous form of moxifloxacin hydrochloride of claim 1, wherein the moxifloxacin hydrochloride has the X-ray diffraction pattern of Figure 2.

4. A pharmaceutical composition comprising:

a therapeutically effective amount of an amorphous form of moxifloxacin hydrochloride; and one or more pharmaceutically acceptable carriers, excipients or diluents.

5. The pharmaceutical composition of claim 1, wherein the moxifloxacin hydrochloride has the infrared spectrum of Figure 1.

6. The pharmaceutical composition of claim 1, wherein the moxifloxacin hydrochloride has the X-ray diffraction pattern of Figure 2.

7. A process for the preparation of the amorphous form of moxifloxacin hydrochloride, the process comprising:

preparing a solution of moxifloxacin hydrochloride in one or more solvents; and

recovering the moxifloxacin hydrochloride in the amorphous form from the solution thereof by the removal of the solvent.

8. The process of claim 7, wherein the solvent comprises one or more of lower alkanol, ketone, chlorinated solvent, or mixtures thereof.

9. The process of claim 8, wherein the lower alkanol comprises one or more of primary, secondary and tertiary alcohol having from one to six carbon atoms.

10. The process of claim 8, wherein the lower alkanol comprises one or more of methanol, ethanol, denatured spirit, n-propanol, isopropanol, n-butanol, isobutanol, and t-butanol.

11. The process of claim 8, wherein the lower alkanol comprises one or more of methanol, ethanol, and denatured spirit.

12. The process of claim 8, wherein the ketone comprises one or more of acetone, 2-butanone, and 4-methylpentan-2-one.

13. The process of claim 8, wherein the chlorinated solvent comprises one or more of chloroform, dichloromethane, and dichloroethane.

14. The process of claim 7, wherein removing the solvent comprises one or more of distillation, distillation under vacuum, evaporation, spray drying, freeze drying, filtration, decantation, and centrifugation.

15. The process of claim 7, wherein the moxifloxacin hydrochloride in an amorphous form is recovered from the solution by spray drying.

16. The process of claim 7, wherein the moxifloxacin hydrochloride in an amorphous form is recovered from the solution by freeze-drying.

17. The process of claim 7, wherein the moxifloxacin hydrochloride in an amorphous form is recovered from the solution by filtration.

18. The process of claim 7, further comprising additional drying of the product obtained.

19. The process of claim 7, further comprising forming the product obtained into a finished dosage form.

20. The process of claim 7, wherein the moxifloxacin hydrochloride has the infrared spectrum of Figure 1.

21. The process of claim 7, wherein the moxifloxacin hydrochloride has the X-ray diffraction pattern of Figure 2.